BMS-303141 - CAS:943962-47-8 - CAS号查询_生物试剂_化学试剂_分析试剂

中文名称:	BMS-303141
英文名称:	BMS 303141
别名:	BMS-303141 3,5-Dichloro-2-hydroxy-N-(4-methoxy[1,1′-biphenyl]-3-yl)-benzenesulfonamide
CAS No:	943962-47-8	分子式:	C₁₉H₁₅Cl₂NO₄S	分子量:	424.3
CAS No:	943962-47-8
分子式:	C₁₉H₁₅Cl₂NO₄S
分子量:	424.3

安全技术说明书(PDF) MSDS(PDF) 点击下载产品说明书(PDF) 点击下载技术规格说明书(PDF)

B10022 BMS-303141 ≥98% (HPLC) (psaitong)

相关产品

包装规格：

5mg 25mg 100mg in glass bottle

溶解性：

溶于DMSO(20mg/mL)

产品描述：

基本信息

产品编号：	B10022
产品名称：	BMS 303141
CAS:	943962-47-8	储存条件	粉末	2-8℃	四年

分子式：	C19H15Cl2NO4S		溶于液体	-80℃	两年
分子量	424.30			-20℃	一个月
化学名：	3,5-Dichloro-2-hydroxy-N-(4-methoxy[1,1′-biphenyl]-3-yl)-benzenesulfonamide
Solubility (25°C)：
体外:	DMSO	85mg/mL(200.32mM)
	Ethanol	Insoluble
	Water	Insoluble
体内(现配现用):	1.请依序添加每种溶剂：10% DMSO→40% PEG300→5% Tween-80→45% saline Solubility:2.5mg/mL(5.89mM);Suspended solution; Need ultrasonic
	此⽅案可获得2.5mg/mL(5.89mM)的均匀悬浊液，悬浊液可⽤于⼝服和腹腔注射。以1mL⼯作液为例，取100μL25.0mg/mL的澄清DMSO储备液加到400μL PEG300中，混合均匀；向上述体系中加⼊50μL Tween-80，混合均匀；然后继续加⼊450μL⽣理盐⽔定容⾄1mL。
	2.请依序添加每种溶剂：10% DMSO→90% (20% SBE-β-CD in saline) Solubility:2.5mg/mL(5.89mM);Suspended solution; Need ultrasonic
	此⽅案可获得2.5mg/mL(5.89mM)的均匀悬浊液，悬浊液可⽤于⼝服和腹腔注射。以1mL⼯作液为例，取100μL25.0mg/mL的澄清DMSO储备液加到900μL20%的SBE-β-CD⽣理盐⽔⽔溶液中，混合均匀。
	3.请依序添加每种溶剂：10% DMSO→90% corn oil Solubility:2.5mg/mL(5.89mM);Suspended solution; Need ultrasonic
	此⽅案可获得2.5mg/mL(5.89mM)的均匀悬浊液，悬浊液可⽤于⼝服和腹腔注射。以1mL⼯作液为例，取100μL25.0mg/mL的澄清DMSO储备液加到900μL⽟⽶油中，混合均匀。
＜1mg/ml表示微溶或不溶。
普西唐提供的所有化合物浓度为内部测试所得，实际溶液度可能与公布值有所偏差，属于正常的批间细微差异现象。
请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；⼀旦配成溶液，请分装保存，避免反复冻融造成的产品失效。

制备储备液

浓度溶液体积质量	1mg	5mg	10mg
1mM	2.3568mL	11.7841mL	23.5682mL
5mM	0.4714mL	2.3568mL	4.7136mL
10mM	0.2357mL	1.1784mL	2.3568mL
50mM	0.0471mL	0.2357mL	0.4714mL

生物活性

产品描述	一种强效的ATP柠檬酸裂合酶（ACL)抑制剂。
靶点	ACL (Cell-free assay) 0.13μM
体外研究	In HepG2 cells, BMS-303141 shows inhibition of total lipid syntheses with an IC50 of 8μM. BMS-303141 shows no cytotoxicity up to 50 lM under a cell based Alamar Blue cytotoxicity assay, indicating the observed inhibition of lipid synthesis is not a result of compound-induced cytotoxicity
体内研究	Chronic oral dosing of BMS-303141 in high-fat fed mice lowers approximate 20-30% plasma cholesterol and triglycerides, as well as 30-50% fasting plasma glucose. Chronic treatment with BMS-303141 shows a gradual inhibition of weight gain along with a reduction in adiposity without apparent changes in food intake. BMS-303141 shows an oral bioavailability of 55% but a relatively short half-life of 2.1 h

推荐实验方法(仅供参考)

Animal Administration

Mice: Effect of BMS-303141 in high-fat fed mice is studied. There are a total of four groups in the study; mice on normal diet and high-fat diet controls, and two treated groups that are supplemented with BMS-303141 in their high-fat diet to an equivalent daily dose of 10 or 100 mg/kg. The study is continued for a total of 34 days. Food consumption and body weight gain are tracked along with weekly assessment of lipid and glucose plasma chemistries

保存条件：

2-8℃

UN码：

HazardClass：

危害声明：

安全说明：

搜索质检报告(COA)

参考文献 & 客户发表文献